Compared with control mice, extended administration of a CXCR4 antagonist to leukaemic mice resulted in a reduction in leukaemia levels in PB and spleens and in the dissemination of ALL cells to extramedullary sites. This evidence concerns the gene CXCR4 and leukemia.